Valsynthese in Grignards collaboration
Swiss fine chemical manufacturer Valsynthese has entered into a manufacturing services agreement, under which it will host Grignard reagents production units based on the proprietary MgFlow Technology of Belgium’s Chemium and offer integrated services based on it. Chemium will commercialise ready-to-use Grignards through its Swiss subsidiary.
MgFlow is described as a “groundbreaking continuous flow process designed especially for the safe manufacturing of Grignard reagents”, featuring temperature control, reduced volumes and new ways of mixing that eliminate the reaction runaway risks that have limited Grignard reagent synthesis. Online QC tools and comprehensive automation can also be integrated into the process.
RELATED ARTICLES
Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4.
Jubilant Ingrevia has commissioned a new 2,000 tonnes/year facility for diketene derivatives at Gajraula in India’s Uttar Pradesh state. The company’s supplies these to the pharmaceuticals, agrochemicals and other industries, including the US and the EU.
EuroAPI has suspended all API production at its site in Brindisi, Italy, until further notice. This followed an internal audit in which “quality control deficiencies due to potential local misconduct” were identified. These are being further investigated.
W.R. Grace has formally opened an expansion of the pharmaceutical CDMO expansion project it began 21 months ago at its site in South Haven, Michigan.
Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.
Noramco, an API supplier specialised in controlled substances, has launched Noramco Group, which it describes as a “comprehensive North American-based supply chain solution” for clinical and commercial APIs and drug products. Noramco Group unites the capabilities of three subsidiaries:
